The purpose of this study is to determine the safety and feasibility of converting patients
to Belatacept monotherapy (receiving just one immunosuppression drug), and to see what
percentage of those patients can be safely converted to once every 8 week administration of
Belatacept. Belatacept has been approved by the Food and Drug Administration (FDA) for kidney
transplant recipients.